You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / CE

SSRI Use in Older Women Linked to Accelerated Hip Bone Loss

  • Authors: News Author: Marlene Busko
    CME Author:
    Désirée Lie, MD, MSEd
  • CME / CE Released: 7/6/2007; Reviewed and Renewed: 7/10/2008
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 7/10/2009
Start Activity


Target Audience and Goal Statement

This article is intended for primary care clinicians, gynecologists, endocrinologists, geriatricians, and other specialists who care for older postmenopausal women.

The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.

Upon completion of this activity, participants will be able to:

  1. Describe the association between selective serotonin reuptake inhibitor use and bone loss in older women.
  2. Describe the association between tricyclic antidepressant use and rate of bone loss in older women.


Disclosures

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Author(s)

  • Marlene Busko

    Marlene Busko is a staff journalist for Medscape Psychiatry. She can be contacted at [email protected]

    Disclosures

    Disclosure: Marlene Busko has disclosed no relevant financial relationships.

CME Author(s)

  • Désirée Lie, MD, MSEd

    Clinical Professor, Family Medicine, University of California, Orange; Director, Division of Faculty Development, UCI Medical Center, Orange, California

    Disclosures

    Disclosure: Désirée Lie, MD, MSEd, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape, LLC designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit(s) . Physicians should only claim credit commensurate with the extent of their participation in the activity. Medscape Medical News has been reviewed and is acceptable for up to 200 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins 09/01/06. Term of approval is for 1 year from this date. This activity is approved for 0.25 Prescribed credits. Credit may be claimed for 1 year from the date of this activity. AAFP credit is subject to change based on topic selection throughout the accreditation year.


    AAFP Accreditation Questions

    Contact This Provider

    For Nurses

  • This Activity is sponsored by Medscape Continuing Education Provider Unit.

    Medscape is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

    Awarded 0.25 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Provider Number: 6FDKKC-PRV-05

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. Medscape encourages you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CME / CE

SSRI Use in Older Women Linked to Accelerated Hip Bone Loss

Authors: News Author: Marlene Busko CME Author: Désirée Lie, MD, MSEdFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME / CE Released: 7/6/2007; Reviewed and Renewed: 7/10/2008

Valid for credit through: 7/10/2009

processing....

July 6, 2007 — In a large observational study of older women — the Study of Osteoporotic Fractures (SOF) — the use of selective serotonin reuptake inhibitor (SSRI) antidepressants but not tricyclic antidepressants (TCAs) was associated with increased hip bone loss.

The study is published in the June 25 issue of the Archives of Internal Medicine.

Lead study author Susan J. Diem, MD, MPH, from the University of Minnesota in Minneapolis, told Medscape, "It would be premature at this point to conclude that SSRIs definitely have an effect on bone health in humans, but this does suggest that this is an area for more research... Clinically, I think this means physicians who have patients who are depressed or who are on SSRIs might consider testing patients' bone mineral density at some point during their treatment."

The group writes that with the development of SSRIs, prescriptions for antidepressants for the elderly have increased substantially during the past 2 decades. Animal studies have shown that SSRIs inhibit serotonin transporters, and this is linked with reduced bone formation rates. However, TCAs act by a different mechanism. The researchers aimed to determine whether SSRI and TCA use in older women is associated with increased rates of hip bone loss.

They examined data from a cohort of women in the SOF study who had hip bone mineral density (BMD) results from their sixth clinic visit (when they were, on average, age 78.5 years) and their the eighth clinic visit (an average of 4.9 years later) as well as results for the 15-item Geriatric Depression Scale.

From 2844 eligible women, 122 women who were taking antidepressants other than SSRIs or TCAs or who were taking both agents were excluded from the analysis.

The remaining 2722 women were classed into 3 groups based on their medication use at visits 6 and 8: nonusers (no SSRI, TCA, or other antidepressant use; n = 2406; 88.4%), SSRI users (no TCA use; n = 198; 7.3%), and TCA users (no SSRI use; n = 118; 4.3%).

Bone mineral density was measured for the total hip and for 2 subregions: the femoral neck and the trochanter.

Greater Bone Loss in SSRI Users

On average, compared with nonusers of SSRIs, women taking SSRIs but not women taking TCAs had a higher rate of bone loss at the total hip, after adjusting for multiple potential confounding factors including age, race, health status, physical activity, smoking status, body mass index, depression, and use of calcium or vitamin D supplements, estrogen, thiazide, or bisphosphonate.

Table. Mean Annualized Rate of Total Hip Bone Loss*

Antidepressant Use Category Mean % Bone Loss Per Year* P
Nonusers .047 (0.42 - 0.53) 1.00
SSRI users 0.82 (0.64 - 1.00) < .001
TCA users 0.47 (0.24 - 0.70) .99


*Adjusted for multiple potential covariables. SSRI indicates selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.
Source: Arch Intern Med. 2007;167:1240-1245.

Bone loss at the femoral neck and trochanter was similar.

Women not taking SSRIs lost bone density at a rate of about 0.5% per year, and the women taking SSRIs lost bone density at a rate of about 0.8% per year, Dr. Diem summarized, adding that "over time, that difference would accumulate, but what is not known is if that difference in rate will translate into an increased risk of fracture, which is what the real issue is."

She cautioned, "We would not recommend people stop taking their antidepressants based on these findings," since this study cannot definitively say whether the SSRIs are directly responsible for the increased rates of bone loss or whether the association may be caused by other factors.

The study was supported by grants from the National Institute on Aging and the National Institute of Arthritis and Musculoskeletal and Skin Diseases. Dr. Diem has disclosed participating in trials funded by Pfizer Inc, Eli Lilly and Co, and Merck & Co, Inc in the area of osteoporosis treatment and prevention. The financial disclosures of the other study authors are listed in the original article.

"Mend the Mind, but Mind the Bones"

Kenneth Saag, MD, MSc, at the University of Alabama in Birmingham, author of an editorial that accompanied this article and another article in the same issue about SSRI use and bone health in men, told Medscape that the fact that these 2 studies about SSRI use and bone health reached very similar conclusions, added to animal data that suggest a biological mechanism, while not conclusive, does begin to suggest a possible cause-and-effect relationship.

He added that to establish a causal link would require a randomized clinical trial, since "unmeasured factors relating to depression, co-illnesses, and other conditions that are not being adequately accounted for in the elegant analyses that these investigators did could potentially cause a finding of this type to be spurious."

Regarding the clinical implications he said, "In patients who are at high risk — women over the age of menopause, men over the age of 70, and in particular, people who have other significant osteoporosis risk factors — it may merit further evaluation of their bone health, which might involve tests such as bone density measurement to determine whether they are indeed in a range where potential treatment may be indicated."

Dr. Saag has disclosed serving as a consultant or speaker for or receiving grant funding in the area of osteoporosis from Merck & Co, Inc, Aventis, Eli Lilly and Co, Novartis, Roche, Arngen, and GlaxoSmithKline.

Arch Intern Med. 2007;167:1231-1232, 1240-1245.

Clinical Context

According to the authors of the current study, antidepressant use has increased substantially in the past 2 decades and SSRIs have supplanted TCAs in the treatment of depression. Recent evidence suggests that functional serotonin transporters affect bone metabolism in osteoblasts, osteoclasts, and osteocytes, according to the authors, and they tested the hypothesis that SSRI or TCA use among older women may affect bone loss. However, depression itself has been associated with bone loss related to reduced mobility and other factors, and it is not clear if SSRI use or depression itself contributes to bone loss in postmenopausal women with depression.

This is a longitudinal cohort study of women older than 65 years who had BMD measured on 2 occasions to determine the association between antidepressant use and bone loss and to compare bone loss among women using SSRIs with that of those using TCA antidepressants.

Study Highlights

  • Community-dwelling women older than 65 years who were enrolled in the SOF trial were included in this study.
  • Of these women, those who completed a medication inventory at 2 visits (visits 6 and 8) and the Geriatric Depression Scale, at visit 6 and who had hip BMD measurements at both visits were included for analysis.
  • Excluded were women who took antidepressants other than SSRIs or TCAs, leaving 2722 women who took either medication and who had 2 BMD measurements.
  • At visits 6 and 8, women were asked to bring all current prescription and nonprescription medications (any use within the past 2 weeks) and interviewers completed a medication history.
  • The average interval between visits 6 and 8 was 4.9 years.
  • Nonusers were defined as those not taking an SSRI, a TCA, or any antidepressant at week 6 or 8.
  • TCA users were defined as those reporting TCA use but not SSRI use at either visit.
  • SSRI users were those reporting SSRI but not TCA or other antidepressant use.
  • Women reporting either SSRI or TCA use at only 1 of these visits were classified as partial users of that medication.
  • Women reporting use of the same medication at both visits were classified as continuous users.
  • BMD at the total hip and 2 subregions (femoral neck and trochanter) were measured at visits 6 and 8 using dual-energy x-ray absorptiometry with bone densitometry scanners.
  • Rate of change of BMD was the primary endpoint and defined as an annualized percentage of the difference between follow-up BMD and initial BMD divided by the initial BMD.
  • Depressive symptoms were evaluated at visit 6 using the 15-item Geriatric Depression Scale, a self-report scale using yes/no questions.
  • A cutoff of 6 or more symptoms on the Geriatric Depression Scale has a sensitivity of 88% and a specificity of 62% for depression.
  • Women also completed a questionnaire on health, smoking status, physical activity, and use of oral hormones, thiazides, bisphosphonates, and vitamin D and calcium supplements.
  • Dietary intake was assessed using a semiquantitative food frequency questionnaire.
  • Functional activity was assessed by asking about 6 independent activities of daily living.
  • Mean age was 78.4 years, 8% to 12% were African American, 7.3% were SSRI users, and 4.3% were TCA users.
  • 88.4% reported no use of an SSRI, TCA, or other antidepressant at either visit.
  • SSRI users were more likely to have a Geriatric Depression Scale score of at least 6 (13.1% vs 5.2%; P < .001).
  • Women taking SSRIs had a higher age-adjusted rate of bone loss at the total hip vs nonusers (-0.77% vs -0.49% per year; P = .005).
  • Results were not changed after adjustment for multiple confounding factors including Geriatric Depression Scale score.
  • At the total hip, femoral, and trochanter sites, the rate of loss of bone was at least 1.6 times higher among SSRI users vs nonusers of antidepressants.
  • Compared with nonusers, partial SSRI users and continuous SSRI users showed no difference in rate of bone loss.
  • The rate of bone loss was -0.47% for nonusers vs -0.83% for partial users vs -0.76% per year for continuous users.
  • Rates of bone loss among TCA users were similar to those of nonusers.
  • The authors noted that the indication for TCA use in this population may differ from that for SSRI use and the number of women using TCAs was small. They suggested that more studies may be needed to verify the observation of lack of association between TCA use and bone loss.

 

Pearls for Practice

  • SSRI use in older women is independently associated with an increased rate of bone loss.
  • TCA use in older women is not associated with increased rate of bone loss.

CME/CE Test

  • Print